Tudor Investment Corp ET AL bought a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,353 shares of the company's stock, valued at approximately $847,000.
Other large investors also recently modified their holdings of the company. Sterling Capital Management LLC boosted its stake in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after buying an additional 503 shares during the period. Tower Research Capital LLC TRC increased its position in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Disc Medicine during the fourth quarter worth approximately $235,000. Teacher Retirement System of Texas boosted its position in shares of Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after purchasing an additional 396 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Disc Medicine during the 4th quarter valued at $309,000. 83.70% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Disc Medicine news, insider William Jacob Savage sold 2,100 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the sale, the insider now directly owns 66,398 shares of the company's stock, valued at $3,331,187.66. This trade represents a 3.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mona Ashiya sold 202,146 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the transaction, the director now owns 208,742 shares of the company's stock, valued at approximately $11,332,603.18. This represents a 49.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 356,290 shares of company stock worth $19,336,901 over the last three months. 4.24% of the stock is currently owned by company insiders.
Disc Medicine Stock Performance
Shares of Disc Medicine stock traded up $1.33 on Monday, hitting $45.57. 66,176 shares of the company's stock were exchanged, compared to its average volume of 348,607. The stock has a market capitalization of $1.58 billion, a PE ratio of -11.54 and a beta of 0.77. Disc Medicine, Inc. has a 1 year low of $30.65 and a 1 year high of $68.73. The company has a 50-day simple moving average of $46.93 and a 200-day simple moving average of $54.98.
Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on IRON shares. TD Cowen began coverage on shares of Disc Medicine in a report on Thursday, February 27th. They set a "buy" rating on the stock. Wedbush reissued an "outperform" rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Morgan Stanley restated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a report on Friday, March 7th. Finally, Scotiabank increased their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine presently has an average rating of "Buy" and an average price target of $93.80.
Get Our Latest Report on IRON
Disc Medicine Company Profile
(
Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
See Also
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
